Ridgeback Biotherapeutics, LP   Report issue

For profit Phase 2
Founded: Miami FL United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04392219
First Marketed Drug
2020
2B1
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

RIDGEBACK BIOTHERAPEUTICS | Ridgeback Biotherapeutics, LP